Global Wine Market 2015-2019 Remains Bullish

Investing in What You Like; Wine Stocks

Global Wine Market 2015-2019 Remains Bullish

Point Roberts WA, NEW YORK, NY – February 3, 2015 - Investorideas.com, a global news source covering leading sectors including beverage stocks releases the updated wine stocks directory for February and an outlook for the sector for 2015-2019.

Wine is still a hot sector according to CompaniesandMarkets.com. In their recent 2015-2019 forecast they report, “One major trend in this market is the increase in demand for sparkling wine. Countries such as Germany, Russia, France, and Italy reported high demand for sparkling wine. New product development and strong product innovations are expected to increase the demand for sparkling wine during the forecast period of 2014-2019. “

“According to analysts, the growth in the Global Wine market is mainly driven by the increased demand for wine in the US. This has increased the market growth both in terms of revenue and volume. A high disposable income, increasing demand for premium wine, and increasing demand for wine among the millennials is driving the market. Also, social acceptance of wine and the various health benefits of wine are boosting the demand for wine in the US.”

Full News Release: http://www.investorideas.com/news/2015/food-beverage/02031.asp

Wine Stocks Preview

Andrew Peller A NV (TSX:ADW-A.TO; ADW-B.TO) is a leading producer and marketer of quality wines in Canada. With wineries in British Columbia, Ontario, and Nova Scotia, the Company markets wines produced from grapes grown in Ontario’s Niagara Peninsula, British Columbia’s Okanagan and Similkameen Valleys, and from vineyards around the world. The Company’s award-winning premium and ultra-premium VQA brands include Peller Estates, Trius, Hillebrand, Thirty Bench, Crush, Wayne Gretzky, Sandhill, Calona Vineyards Artist Series, and Red Rooster. Complementing these premium brands are a number of popularly priced varietal wine brands including Peller Estates French Cross in the East, Peller Estates Proprietors Reserve in the West, Copper Moon, XOXO, skinnygrape and Verano. Hochtaler, Domaine D’Or, Schloss Laderheim, Royal, and Sommet are our key value priced wine blends. The Company imports wines from major wine regions around the world to blend with domestic wine to craft these popularly priced and value priced wine brands. With a focus on serving the needs of all wine consumers, the Company produces and markets premium personal winemaking products through its wholly-owned subsidiary, Global Vintners Inc., the recognized leader in personal winemaking products. Global Vintners distributes products through over 250 Winexpert and Wine Kitz authorized retailers and franchisees and more than 600 independent retailers across Canada, the United States, the United Kingdom, New Zealand, and Australia. Global Vintners award-winning premium and ultra-premium winemaking brands include Selection, Vintners Reserve, Island Mist, Kenridge, Cheeky Monkey, Ultimate Estate Reserve, Traditional Vintage, Cellar Craft, and Artful Winemaker. The Company owns and operates more than 100 well- positioned independent retail locations in Ontario under the Vineyards Estate Wines, Aisle 43, and WineCountry Vintners store names. The Company also owns Grady Wine Marketing Inc. based in Vancouver and The Small Winemaker’s Collection Inc. based in Ontario; both of these wine agencies are importers of premium wines from around the world and are marketing agents for these fine wines. The Company has entered into a partnership to market the Wayne Gretzky Estate Winery brands across Canada. The Company’s products are sold predominantly in Canada with a focus on export sales for its icewine and personal winemaking products.

AUSTRALIAN VINTAGE LTD (ASX:AVG.AX) is a leading Australian wine company. Championing a fully-integrated wine business model, the breadth of our capabilities extends to vineyards, boutique and bulk wine production, packaging, marketing and distribution

BROWN FORMAN INC A (NYSE:BF-A; BF-B) For more than 140 years, Brown-Forman Corporation has enriched the experience of life by responsibly building fine quality beverage alcohol brands, including Jack Daniel’s Tennessee Whiskey, Southern Comfort, Finlandia, Jack Daniel’s & Cola, Canadian Mist, Korbel, Gentleman Jack, el Jimador, Herradura, Sonoma-Cutrer, Chambord, New Mix, Tuaca, and Woodford Reserve. Brown-Forman’s brands are supported by nearly 4,200 employees and sold in approximately 160 countries worldwide.

Chapel Down Group plc (ISDX:CDGP) produces and markets a range of still and sparkling wines made from English grapes. Whilst most are white wines, the proportion of red and sparkling wines has been increasing steadily. The Company operates a production site, vineyard and retail outlet at Tenterden in Kent. Most of the Group's grapes are purchased from specialist producers across the South-East of England.

China Tontine Wines Group Limited  (Hong Kong:0389.HK; OTC:CATWF) has grown rapidly since its inception in 2001. It has been the leading sweet wines producer in the PRC in terms of volume for five consecutive years since 2008 and is also one of the Top 10 PRC Grape Wine Industry Brands. The Group sells wine products in two main categories – sweet wines and dry wines under the “Tongtian”, “Tongtian Hong” and “TONTINE” labels. The Group gets its grape supply from the Tonghua Ji’An region, a major mountain grapes producing area in the PRC and one of the few regions worldwide where mountain grapes can be cultivated. With its stringent quality control system, the Group strongly emphasizes the quality of its products. It was awarded the “Annual Brand in China Grape Wine Market” in 2013. After the Group’s acquisition of the 60% stake in Yantai Baiyanghe in December 2013, it now produces and sells more than 100 types of winery products, covering a variety of grape wines and brandies, including high quality imported grape wines from France (e.g., “Cordes”, “Falyia”, etc.). Through a sales network comprising more than 100 distributors, the Group sells its products in 22 provinces, 3 autonomous regions and 4 municipalities in the PRC. Under the leadership of the experienced management team, Tontine Wines is dedicated to becoming a sweet wine expert in the PRC.

Citic Guoan Wine Co Ltd (Shanghai:600084.SH) is principally engaged in the production and distribution of wine. Through its subsidiaries, the Company is involved in the farming of grapes, the distribution of wine, the processing and filing of wine, as well as the manufacturing of fruit juice wine, among others. The Company primarily offers grape wines with brands named NIYA, Strong and WESTERN, among others.

Compania Cervecerias Unidas S.A. (NYSE: CCU) is a diversified beverage company operating principally in Chile and Argentina. CCU is the largest Chilean brewer, the second-largest Argentine brewer, the second-largest Chilean soft drink producer, the second-largest Chilean wine producer, the largest Chilean mineral water and nectars producer, the largest pisco distributor and also participates in the rum and confectionery industries in Chile. The Company has licensing agreements with Heineken Brouwerijen B.V., Anheuser-Busch Incorporated, PepsiCo Inc., Paulaner Brauerei AG, Schweppes Holdings Limited, Guinness Brewing Worldwide Limited, Société des Produits Nestlé S.A., Pernod Ricard and Compañía Pisquera Bauzá S.A..

Constellation Brands (NYSE: STZ; NYSE:STZ-B) based in Victor, New York, is a leading wine, beer and spirits company with a broad portfolio of premium brands. Constellation is the world leader in premium wine, the number one beer importer and the number three beer company in the U.S Constellation Brands is an S&P 500 Index and Fortune 1000® company with more than 100 brands in our portfolio, sales in approximately 100 countries and operations in approximately 40 facilities.

Corby Distilleries Limited (TSX:CSW-A.TO; CSW-B.TO) is a leading Canadian marketer of spirits and imported wines. Corby's portfolio of owned-brands includes some of the most renowned brands in Canada, including Wiser's® Canadian whisky, Lamb's® rum, Polar Ice® vodka and McGuinness® liqueurs. Through its affiliation with Pernod Ricard S.A., Corby also represents leading international brands such as ABSOLUT® vodka, Chivas Regal® The Glenlivet® and Ballantine's® Scotch whiskies, Jameson® Irish whiskey, Beefeater® gin, Malibu® rum, Kahlua liqueur, Mumm champagne, and Jacob's Creek®, Wyndham Estate®, Stoneleigh®, Campo Viejo®, Graffigna® and Kenwood® wines.

Full directory see: http://www.investorideas.com/membership/

InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors  

http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com

800 665 0411

Recent Biotech IPO’s; (ASND), (ENTL), (FLKS), (ONCE), (TCON), (ZSAN)

Recent Biotech IPO’s; (ASND), (ENTL), (FLKS), (ONCE), (TCON), (ZSAN)

Point Roberts WA, NEW YORK, NY – February 3, 2015 - Investorideas.com, a global news source covering leading sectors including biotech and medical technology stocks reports on the recent IPO’s in the sector. The flood of IPO’s is making experts ask if a biotech bubble is being created. With up to 100 IPO’s in the works for this year, time will tell.

Here is a look at some of the recent listings:

Ascendis Pharma (NASDAQ:ASND) completed its initial public offering of 6,900,000 American Depositary Shares (ADSs) at a price to the public of $18.00 per ADS. The stock is currently trading at $19.04. Ascendis Pharma A/S is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Entellus Medical Inc (NASDAQ:ENTL) began trading on The NASDAQ Stock Market on January 29, 2015. The IPO consisted of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share Entellus is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. The XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. The stock is currently trading at $21.52.

On January 28^th Flex Pharma Inc (NASDAQ: FLKS) announced its initial public offering of 5,400,000 shares of common stock at a public offering price of $16.00 per share. Flex Pharma, Inc. is a biopharmaceutical company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions.

January 30^th Spark Therapeutics Inc (NASDAQ:ONCE)  announced its offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. Spark is a late clinical-stage gene therapy company seeking to develop one-time, life-altering treatments for debilitating genetic diseases, with an initial focus on treating rare diseases. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. The stock is trading at $45.82 this morning.

TRACON Pharmaceuticals Inc (NASDAQ:TCON) IPO consisted of 3,600,000 shares of common stock at a price to the public of $10.00 per share. TRACON develops targeted therapies for cancer, age‐related macular degeneration and fibrotic diseases. TRACON’s current pipeline includes two clinical stage product candidates: TRC105, an antiendoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. The stock is currently trading below its IPO price. 

Zosano Pharma Corp (NASDAQ:ZSAN) completed its offering of 4,500,000 shares of common stock at a price to the public of $11.00 per share. The stock is trading at $11.06 in this morning’s session. Zosano Pharma Corporation is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications. Zosano's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies.

InvestorIdeas.com newswire is a global recognized news source. We publish original content, third party investment commentary, contributor articles, company news and press releases in leading sectors.

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors  

http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com

800 665 0411

SHAKE SHACK (NYSE: SHAK) Soars on Market Debut; Investors Eating Up Those Burgers

IPO News: SHAKE SHACK (NYSE: SHAK) Soars on Market Debut; Investors Eating Up Those Burgers

New York NY- Point Roberts WA–January 30,2015 – (www.investorideas.com newswire,) Investorideas.com staff: Investorideas.com, a global news  source covering leading sectors including food and beverage stocks reports on the market debut of Shake Shack IPO (NYSE:SHAK).

The stock is trading at $48.54, up $27.54(131.14%) as of 12:12PM EST.

The IPO consisted of 5,000,000 shares of its Class A common stock at a public offering price of $21.00 per share. In addition, Shake Shack has granted the underwriters a 30-day option to purchase from Shake Shack up to an additional 750,000 shares of its Class A common stock at the initial public offering price, less the underwriting discount.

The closing of the offering is expected to occur on February 4, 2015, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint lead book-running managers in the proposed offering. Barclays Capital Inc., Goldman, Sachs & Co., and Jefferies LLC are also acting as book-running managers in the proposed offering. William Blair & Company, L.L.C. and Stifel are acting as co-managers in the proposed offering.

About Shake Shack

Shake Shack® is a modern day “roadside” burger stand known for its delicious burgers, hot dogs, frozen custard, crinkle cut fries, beer, wine and more. With its fresh, simple, high-quality food at a great value, Shake Shack is a fun and lively community-gathering place with widespread appeal. From its premium ingredients and progressive hiring practices to its environmentally responsible designs and deep community investment, Shake Shack’s mission is to Stand For Something Good®. Since the original Shack opened in 2004 in NYC’s Madison Square Park, the Company has opened additional company-operated Shacks in New York, New Jersey, Washington, D.C., Connecticut, Georgia, Illinois, Pennsylvania, Florida, Massachusetts, Virginia, and Nevada, and international licensed Shacks in London, Istanbul, Dubai and more.

Read this release in full at http://www.investorideas.com/news/2015/food-beverage/01301.asp

About InvestorIdeas.com:

InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and use our online stock directories to research stocks – including biometric and mobile payment stocks http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

800-665-0411

Source – www.Investorideas.com

Box, Inc NYSE Tech Stock Market Debut: (NYSE:BOX) Soars on Opening

Box, Inc NYSE Tech Stock Market Debut: (NYSE:BOX) Soars on Opening

New York NY- Point Roberts WA–January 23, 2015– (www.investorideas.com newswire) Investorideas.com, a global news  source covering leading sectors  including technology and tech stocks reports on the IPO and market debut of Box, Inc. (NYSE:BOX) a provider of enterprise cloud-based product platform.

Box is another big tech name that decided to list on NYSE instead of the traditional tech NASDAQ IPO.

The stock opened up strong and is currently trading at $ 22.92 up $8.92(63.75%).

They announced the pricing of its initial public offering of 12,500,000 shares of its Class A common stock at a price to the public of $14.00 per share. In addition, Box granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Class A common stock to cover over-allotments.

Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC are acted as joint book-running managers for the offering, BMO Capital Markets Corp. acted  as lead manager, and Canaccord Genuity Inc., Pacific Crest Securities LLC, Raymond James & Associates, Inc. and Wells Fargo Securities, LLC acted  as co-managers.

Read this release in full at http://www.investorideas.com/news/2015/technology/01231.asp

About Box

Box’s mission is to make businesses of all sizes more productive, competitive, and collaborative by connecting people and their most important information. Content on Box can be securely shared and easily accessed on the web and through mobile applications, and extended to partner applications, such as NetSuite and Salesforce. Headquartered in Los Altos, CA, Box is privately held and backed by several leading venture capital firms and strategic investors. To learn more about Box, visit www.box.com.

About InvestorIdeas.com:

InvestorIdeas.com is a global news source for investors following leading business sectors including technology and related stocks.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and use our online stock directories to research stocks – including biometric and mobile payment stocks http://www.investorideas.com/membership/

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

800-665-0411 - Source – www.Investorideas.com

Breaking Tech News: NXT-ID (OTCQB: NXTD) Resumes CNBC Ad Campaign for its Next Generation Smart Wallet, Wocket™; to Commence Week of July 7th

SHELTON, Conn. - June 30, 2014 (Investorideas.com Newswire) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, is pleased to announce that the second series of 30 second spots on CNBC for its next generation smart wallet, Wocket™, will begin the week of July 7th.

The new ad, "Introducing Wocket™, the Smart Wallet", will air on Squawk Box, Squawk on the Street and Street Signs. The ad focuses on the visual of a big fat bulky wallet ending up in the wrong hands with your most personal information all gone; your credit cards, your membership cards, gift cards, all gone. Replacing them is a nightmare. It then poses the question," what if there was a better way? "
Wocket™ is a smart wallet, the next evolution following the smart phone and smart watch. NXT-ID is introducing its innovative, patent-pending Wocket™ as the next natural step in the evolution of smart devices. Wocket™ is a next generation smart wallet designed to protect your identity and replace all the cards in your wallet, with no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval.
Credit, debit, ATM, loyalty, gift, ID, membership, insurance, ticket, emergency, medical, business, contacts, coupon, and virtually any card can be protected on Wocket™. More than 10,000 cards, records, coupons, etc. and 100 voice commands can also be stored on Wocket™.
Wocket™ is now available for advance ordering at www.wocketwallet.com at a price of $149.99.
The full Wocket product FAQ is available to consumers and media at http://nxt-id.com/wocket-faq/
About NXT- ID Inc. -Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™ ; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.wocketwallet.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Corporate info: info@nxt-id.com
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
ksmith@proactivecapital.com
Media: 800 665-0411
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech Media Advisory: GenSpera (OTCQB:GNSZ) 2014 BIO International Presentation Available

SAN ANTONIO - June 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.
Summary:

• G-202 Data in Hepatocellular (HCC) Patients (Ph I and Ph II)
• All patients previously progressed on, or were intolerant of, sorafenib
• Outstanding clinical safety profile
• Well tolerated with easily managed and predictable side effects
• No effect on bone marrow!
• 80% of patients with stable disease (no tumor growth) at two months
• 50% of patients with stable disease for ≥ 4 months
• Long-term disease stabilization (≥ 9 months) in 15% of patients
• One patient remains on treatment > 22 months
• End of bone pain in one patient with vertebral metastasis

The full BIO presentation is available for view at: http://www.genspera.com/press/140620_GNSZ_BIO_Presentation_June_24_2014.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
About BIO
The 2014 BIO International Convention was held June 23-26 at the San Diego Convention Center in San Diego, California.
The BIO International Convention was hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. http://convention.bio.org/2014/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
210-479-8112
Investors:
John Baldissera
BPC Financial Marketing
800-368-1217
Media: (800) 665 0411
Disclaimer/ Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18,2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Breaking Tech News: Analyst Update; NXT-ID Inc. (OTCQB: NXTD) Wocket Launches into Waiting Market

BOSTON - June 26, 2014 (Investorideas.com Newswire) SoundView Technology Group releases the recent research update on NXT-ID Inc. (OTCQB: NXTD) and its smart wallet, Wocket™.

Recent developments following the June 11th update include the Company has filed for a NASDAQ application and appointed a new independent Board member to satisfy that requirement for listing.
Wocket Launches into Waiting Market
Kris Tuttle & Stephen Waite – June 11, 2014
Summary: The Wocket™ was officially launched on May 28th at the Plaza Hotel in NYC. All the feedback we received from attending suggests that consumers who get a chance to see and understand it, immediately want one. It's a viable way to deliver something consumers can use as a digital wallet that is secure, private, and able to handle all their payment, identification, and loyalty needs. The Wocket is really a wallet replacement, and the functional demonstration worked very well. We'll be monitoring the progress and consumer reaction very closely over the next few months with an eye to validating our IV model, which currently suggests a stock value of $11.70/share. We have also extended our forecast to arrive at a projected IV in 2015 of $20.55.
Additional Details: As a prelude to what will be a more active marketing phase, the event included attendance by the media, investors, analysts, and Miss Universe 2012, which added a special level of energy and media attention.
In addition to elaborating on the key features, there was a live demonstration of using the Wocket to do a typical transaction by swiping the card, just as one does with a standard plastic debit or credit card.
Online preorders are available with first units shipping to consumers in September at a price of $149.99, plus some optional services for customers that require additional protection.
Wocket is NXT-ID's replacement for a conventional wallet. The heart of it is the device itself which securely stores cards digitally – that covers virtually all of the important cards consumers carry in a wallet today, including credit, debit, ATM, loyalty, gift, ID, membership, insurance, medical information, and coupons. Wocket locks a user's private information in an electronic "vault" where only an authenticated owner can authorize access to the data. The case provides some space for cash and a driver's license.
As concerns continue to mount in the U.S. and around the world about identity theft and data hacking, the timing of the launch of the Wocket helps NXT-ID channel media attention into their marketing strategy. The Wocket addresses the important issues not adequately addressed currently by smart phones and other mobile devices.
The biggest advantages are in authentication and security. The Wocket uses biometric technology to provide identity protection and security. All information used with the Wocket is encrypted by the owner's personal biometric stamp. NXT-ID is a pioneer in biometric technology, and the Wocket incorporates some of the most advanced biometric technology on the market (see our report, "Mobile Security Beyond the Password", for an in depth discussion of the technology). The device protects whatever information is stored in it so that it cannot be released to any other individual or device without the user's permission.
All payment cards and other dynamic stripe cards are swiped directly into the Wocket during the initial set-up process. Barcodes and text, such as voter's registration, loyalty and/or membership cards, may all be scanned or entered into the Wocket. All information is encrypted by the owner's personal biometric stamp and can be accessed via a low power touch screen or optionally, a voice command.
Information is placed on a tamper-proof encrypted chip inside the Wocket rather than on anywhere in the cloud. Any attempt to access the encrypted chip will result in destroying any information stored on it.
If a Wocket or Wocket card is stolen, the company can guarantee that the Wocket is worthless to anyone besides its owner. The security technology incorporated by the Wocket zeroes out any relevant information on the card dynamically after each use. Hence, the card used with the Wocket becomes a blank piece of plastic to a thief. For added peace of mind, NXT-ID will be offering customers an insurance plan for stolen, misplaced, or lost Wockets.
The Wocket can securely store up to 10,000 items including – debit/credit/loyalty/gift cards, health information, coupons, and miscellaneous records.
Battery life is expected to be one year or more, depending on frequency of use. A light will appear on the device weeks before the battery is due for replacement, so users can replace the conventional lithium ion battery that is widely available at a variety of retail stores around the world.
NXT-ID has an FAQ section on the Wocket website that addresses key questions and issues associated with the device (see: http://wocketwallet.com).
NXT-ID has started taking pre-orders for the Wocket on their website, with plans to ship the first devices in September. Unlike many digital devices on the market today, the Wocket is being manufactured in America. NXT-ID is planning a significant promotional campaign this summer to increase customer awareness and drive more pre-sales.
Sales Projections and Intrinsic Valuation: Over the past year we've seen plenty of data showing that there is strong desire for a device like the Wocket. Consumers are still waiting for an actual product to buy and use. Initial sales volumes will depend on initial orders, and initially, on the ability of NXT-ID to ramp production and manage some longer lead time components.
After a review of our current projections and intrinsic valuation (IV) model, we don't see anything that needs to be changed. However, extending the projections and model out an additional year allows us to publish a 2015 IV estimate of $20.55.
Our current estimate for sales in 2014 is 40K units, which grow fast in later years to reach nearly 1M units in 2018 and 1.5M units in 2019. These unit projections are still very low considering the small penetration rate needed to generate those numbers. If the Wocket is successful, unit growth can be much faster. Many investors were surprised by how quickly new categories like the iPad reached large numbers of units after consumer adoption. We won't have any real visibility on these longer term projections until 2015, but have a credible working forecast to start with.
Although digital currencies are not the initial focus for the Wocket, we were impressed with the figures showing consumer adoption of bitcoin wallets grew from under 500K to over 5M in one year!
Conclusion: The official launch of the Wocket has certainly increased our confidence in the IV model shown below. As consumers begin to use the device in the real world, we'll know much more.
There's huge demand to use digital payments and have a secure digital wallet that is easy to use and genuinely safe. Consumers are nearly clamoring for it. Although other companies have done Kickstarter campaigns and showed slick videos, the NXT-ID Wocket will be helping to define this market in the next few months.
The stock has been holding steady after a major post-IPO run, but our IV clearly shows there is far more to go if the Wocket is delivered on time and consumers have a good experience with it.
About SoundView Research
SoundView conducts independent research in emerging technologies. Our approach is to combine major thematic forces where technology is involved and use analysis to identify the most promising companies and investment opportunities.
Our business model is combination of advisory fees, subscriptions and shared revenue agreements. We measure our success by the quality of our analysis, accuracy of the conclusions and the size and influence of our audience. We apply our own proven approach to valuation that we call intrinsic value (IV) for informing investment decisions and optimizing portfolio management.
Full report with images and graphs: http://s3.amazonaws.com/Published_Research/NXT-ID_NXTD_Update_Note_Final_June_2014.pdf
Important Disclosures
The analysts who prepared this report certify that the content expresses accurately their personal views and opinions about the subject companies and securities. The analysts have not been and will not be receiving direct or indirect compensation for expressing the specific views or conclusions in this report.
Except where otherwise noted, clients or affiliates of SoundView Research may own positions in the securities mentioned and/or provide, have provided or may provide advisory services to some of the companies mentioned.
SoundView Research does not provide investment advice in the form of "buy," "sell," or "hold" ratings. This report is intended strictly for informational purposes. We make no claims as to the completeness or accuracy of this report although we have done our best. We do not undertake to advise you of any changes in our opinion or information contained herein.
SoundView is NOT a registered securities broker/dealer, investment bank nor investment advisory.
SoundView Technology Group does receive advisory fees, has vested interests and/or may have embedded biases in our work. However our aim is on what we call "fact-based research" and providing a balanced and informed analysis that provides illumination and insight for investors.
SoundView Research is solely responsible for all content– whether it is created for a third party, part of an advisory engagement or simply an expression of our ongoing research and analysis. We exercise final editorial control over all content produced and any mistakes, omissions or errors are our own.
Our research is distributed to institutions, investors, company managers and individuals via proprietary platforms1 and via the internet and social networks. We embrace the online community and social and professional networks to engage with colleagues, clients and investors.
SoundView maintains additional online brands for specialty research products including IPO Candy, Dealipedia and Research 2.0. We also collaborate and share with research partners like GigaOM.
Contact Information
Main Address: SoundView Technology Group, 1313 Washington St., 326, Boston MA 02118
Phone: +1-617-828-6462
Website: http://www.soundview.com
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of June 2014, NXT-Id renewed for five thousand per month and average of two thousand five hundred 144 shares (cash equivalent) for news publication and marketing of Wocket smart wallet. More info: http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Online Access to Infectious Disease and Cancer Therapy Presentation

SAN DIEGO - June 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.

The presentation covered the following topics:

• A status report on the first FDA approved study of Hemopurifier therapy in the United States, including Aethlon's clinical progression strategy to advance infectious disease and oncology treatment indications.
• A review of clinical safety data and efficacy observations resulting from Hemopurifier administration to HIV and Hepatitis c (HCV) infected individuals.
• The results of government and non-government collaborative testing programs against category "A" bioterror and pandemic threats, including pandemic influenza, dengue, ebola, pox viruses, and other viral pathogens that remain untreatable with drug or vaccine therapies.
• The discovery that the Aethlon Hemopurifier captures tumor-secreted exosomes underlying a broad-spectrum of cancer indications and the resulting patent protection already issued to protect Aethlon's cancer treatment endeavors.
• A review of a National Cancer Institute (NCI) sponsored publication that references Aethlon Medical as the first organization with a therapeutic candidate to address tumor-secreted exosomes.
• A review of recent landmark discoveries that tumor-secreted exosomes suppress the immune system of cancer patients, seed the creation and spread of metastasis, promote angiogenesis, and transport PD-1, PDL-1, VEGF, CTLA-4, EGRF and other primary cancer therapeutic targets of the biopharmaceutical industry.
• The central role of the Aethlon Hemopurifier in the rapidly emerging immuno-oncology industry, which analysts expect to grow to $35 billion per year in the near future.
• The recent launch of Aethlon's Exosome Sciences diagnostic subsidiary, which is the first organization to demonstrate the ability to isolate exosomes that transport diagnostic biomarkers underlying alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), and glioblastoma multiforme (GBM) that have crossed through blood brain barrier into the circulatory system. Thus, setting the stage for liquid biopsies that allow for the identification and monitoring of these disease conditions.

About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com or www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Get free news alerts: Sign up here
Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.